Antibody · 혈액암 (AML/ALL)

166개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved166 programs
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab+cetuximab (Toripalimab+cetuximab)

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma · Patients With Locally Recurrent Resectab

#PatientsWithLocallyRecurrentRese#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleCentre Hospitalier Universitair…Phase 2

nivolumab (Opdivo, UCPVax + Nivolumab)

Advanced Non-small Cell Lung Cancer · Advanced Non-small Cell Lung Cancer

#AdvancedNon-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Centre
Trials 1Status Active
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 3

Uliledlimab (Uliledlimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#TJ
Trials 1Status Recruiting
AntibodyLimited DatastaleMersana TherapeuticsPhase 3

Upifitimab rilsodotin (Upifitimab rilsodotin)

High Grade Serous Ovarian Cancer; Fallopian Tube Cancer · High Grade Serous Ovarian Cancer

#HighGradeSerousOvarianCancer#Antibody#Phase3#monoclonal-antibody#FallopianTubeCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#monoclonal-antibody#Beijing
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

Varlilumab (Varlilumab)

Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma · Metastatic Distal Bile Duct Adenocarcino

#MetastaticDistalBileDuctAdenocar#Antibody#Phase2#monoclonal-antibody#MetastaticGallbladderCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCatalYm GmbHPhase 2

Visugromab (Visugromab)

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCatalYm GmbHPhase 2

recommended dose for expansion (Visugromab RDE, Visugromab RDE (recommended dose for expansion))

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleXencor, Inc.Phase 2

pembrolizumab (Keytruda, XmAb18087 ± Pembrolizumab)

Merkel Cell Carcinoma; Small Cell Lung Cancer · Merkel Cell Carcinoma

#MerkelCellCarcinoma#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleGilead SciencesPhase 2

ZIM (Zimberelimab, Zimberelimab (ZIM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#monoclonal-antibody#AdvancedorMetastaticNon-Small-Ce+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu Cancer Institute & Hosp…Phase 2

QL1706 (apalolimab and toripalimab, apalolimab and toripalimab (QL1706))

NSCLC; NSCLC (Non-small Cell Lung Cancer) · NSCLC

#NSCLC#Antibody#Phase2#monoclonal-antibody#NSCLCNon-smallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NoncontiguousStageIISmallLymphoc+2
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, atezolizumab / tiragolumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleAmgenPhase 1

blinatumomab and auto-HSCT "sandwich " strategy (blinatumomab and auto-HSCT "sandwich " strategy)

B-cell Acute Lymphoblastic Leukemia · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#Antibody#Phase1#monoclonal-antibody#Amgen
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

cisplatin, vinorlebine, cetuximab (cisplatin, vinorlebine, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

cisplatine, etoposide, cetuximab (cisplatine, etoposide, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

cixutumumab (cixutumumab)

Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer

#RecurrentNon-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#StageIIIBNon-smallCellLungCancer+1
Trials 1Status Active
AntibodyLimited DatastaleStanford UniversityPhase 1

dupliumab (dupliumab)

Eosinophilic Disorder; Food Allergy · Eosinophilic Disorder

#EosinophilicDisorder#Antibody#Phase1#monoclonal-antibody#FoodAllergy+1
Trials 1Status Discontinued
AntibodyLimited DatastalePfizerPhase 3

gemtuzumab ozogamycin (gemtuzumab ozogamycin)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#Antibody#Phase3#monoclonal-antibody#Pfizer
Trials 1Status Active
AntibodyLimited DatastaleArrys TherapeuticsPhase 2

pembrolizumab (Keytruda, grapiprant and pembrolizumab)

Non-small Cell Lung Cancer Adenocarcinoma · Non-small Cell Lung Cancer Adenocarcinom

#Non-smallCellLungCancerAdenocarc#Antibody#Phase2#monoclonal-antibody#Arrys
Trials 1Status Discontinued

8 / 9 pages

← PreviousNext →